Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William P Hanage

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
Human Vaccines & Immunotherapeutics|February 25, 2016
Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacementWilliam P Hausdorff, William P Hanage
The Lancet. Infectious Diseases|November 30, 2019
Pneumococcal conjugate vaccines in different settings - Authors' replyWilliam P Hanage, Joseph A Lewnard
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2023
Human behavior and disease dynamicsCarl T Bergstrom, William P Hanage
Nature|May 12, 2026
Bacterial-viral conflicts shape cholera evolutionIndra González Ojeda, William P Hanage
The New England Journal of Medicine|February 2, 2022
Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron VariantRoby P Bhattacharyya, William P Hanage
The New England Journal of Medicine|April 20, 2022
Intrinsic Severity of the SARS-CoV-2 Omicron Variant. ReplyRoby P Bhattacharyya, William P Hanage
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2019
Potential for Erosion of Efficacy in Noninferiority Trials of Decreasing Duration of Antibiotic TherapyDerek R MacFadden, William P Hanage
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2019
Streptococcus pyogenes With Reduced Susceptibility to β-Lactams: How Big an Alarm Bell?William P Hanage, Samuel A Shelburne
Science (New York, N.Y.)|April 23, 2021
Partial immunity and SARS-CoV-2 mutationsWilliam P Hanage, Colin A Russell
The Lancet. Microbe|August 25, 2020
Reproducibility in science: important or incremental?Robyn S Lee, William P Hanage
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
Human Vaccines & Immunotherapeutics|February 25, 2016
Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacementWilliam P Hausdorff, William P Hanage
The Lancet. Infectious Diseases|November 30, 2019
Pneumococcal conjugate vaccines in different settings - Authors' replyWilliam P Hanage, Joseph A Lewnard
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2023
Human behavior and disease dynamicsCarl T Bergstrom, William P Hanage
Nature|May 12, 2026
Bacterial-viral conflicts shape cholera evolutionIndra González Ojeda, William P Hanage
The New England Journal of Medicine|February 2, 2022
Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron VariantRoby P Bhattacharyya, William P Hanage
The New England Journal of Medicine|April 20, 2022
Intrinsic Severity of the SARS-CoV-2 Omicron Variant. ReplyRoby P Bhattacharyya, William P Hanage
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2019
Potential for Erosion of Efficacy in Noninferiority Trials of Decreasing Duration of Antibiotic TherapyDerek R MacFadden, William P Hanage
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2019
Streptococcus pyogenes With Reduced Susceptibility to β-Lactams: How Big an Alarm Bell?William P Hanage, Samuel A Shelburne
Science (New York, N.Y.)|April 23, 2021
Partial immunity and SARS-CoV-2 mutationsWilliam P Hanage, Colin A Russell
The Lancet. Microbe|August 25, 2020
Reproducibility in science: important or incremental?Robyn S Lee, William P Hanage
Pageof 23